Intranasal delivery of stem cells as therapy for central nervous system disease

被引:55
|
作者
Li, Yan-hua [1 ]
Feng, Ling [1 ]
Zhang, Guang-Xian [3 ]
Ma, Cun-gen [1 ,2 ]
机构
[1] Shanxi Datong Univ, Inst Brain Sci, Sch Med, Dept Neurol, Datong 037009, Peoples R China
[2] Shanxi Univ Tradit Chinese Med, Dept Encephalopathy, Collaborat Innovat Ctr 2011, Natl Major Clin Dept,Minist Hlth, Taiyuan 030024, Peoples R China
[3] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA
基金
美国国家卫生研究院;
关键词
Stem cells; Intranasal; CNS disease; TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPRESSING CHOLINE-ACETYLTRANSFERASE; APOPTOSIS-INDUCING LIGAND; NEURAL PROGENITOR CELLS; PARKINSONS-DISEASE; BONE-MARROW; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; RAT MODEL;
D O I
10.1016/j.yexmp.2015.01.016
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Stem cells, upon entering the CNS, can preferentially migrate into disease foci, where they exert therapeutic effects that compensate for lost tissue, reconstructing damaged neuronal circuitry and establishing in the brain a new microenvironment suitable for cell survival. However, the route of stem cell delivery into the CNS remains a challenge: with systemic administration (e.g., intravenous injection), a fraction of cells may be trapped in other organs than the CNS, while direct CNS injections, e.g., intracerebroventricular or transcranial, are invasive. Intranasal (i.n.) delivery of stem cells, in contrast, can effectively bypass the blood-brain barrier, rapidly enter the CNS, and minimize systemic distribution. I.n. delivery of stem cells may therefore be a safe and non-invasive way of targeting the CNS and would thus be a promising therapeutic option for CNS disease. In this review we discuss the i.n. route for stem cell delivery into the CNS, and the perspectives of i.n. stem cell-based therapy in CNS disease. (C) 2015 Elsevier Inc All rights reserved.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 50 条
  • [41] Stem cells of the enteric nervous system: causal therapy for Hirschsprung's disease?
    Sommer, L.
    PATHOLOGE, 2007, 28 (02): : 125 - 129
  • [42] Intranasal administration of stem cell-derived exosomes for central nervous system diseases
    Shuho Gotoh
    Masahito Kawabori
    Miki Fujimura
    NeuralRegenerationResearch, 2024, 19 (06) : 1249 - 1255
  • [43] Intranasal administration of stem cell-derived exosomes for central nervous system diseases
    Gotoh, Shuho
    Kawabori, Masahito
    Fujimura, Miki
    NEURAL REGENERATION RESEARCH, 2024, 19 (06) : 1249 - 1255
  • [44] Immunological Barriers to Stem Cell Therapy in the Central Nervous System
    Tullis, Gregory E.
    Spears, Kathleen
    Kirk, Mark D.
    STEM CELLS INTERNATIONAL, 2014, 2014
  • [45] Intranasal erythropoietin therapy in nervous system disorders
    Genc, Sermin
    Zadeoglulari, Zeynep
    Oner, Meryem Gulfem
    Genc, Kursad
    Digicaylioglu, Murat
    EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (01) : 19 - 32
  • [46] Radiation therapy for benign central nervous system disease
    Tsao, MN
    Wara, WM
    Larson, DA
    SEMINARS IN RADIATION ONCOLOGY, 1999, 9 (02) : 120 - 133
  • [47] Methods of Generation of Induced Pluripotent Stem Cells and Their Application for the Therapy of Central Nervous System Diseases
    Cherkashova, E. A.
    Leonov, G. E.
    Namestnikova, D. D.
    Solov'eva, A. A.
    Gubskii, I. L.
    Bukharova, T. B.
    Gubskii, L. V.
    Goldstein, D. V.
    Yarygin, K. N.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 168 (04) : 566 - 573
  • [48] Methods of Generation of Induced Pluripotent Stem Cells and Their Application for the Therapy of Central Nervous System Diseases
    E. A. Cherkashova
    G. E. Leonov
    D. D. Namestnikova
    A. A. Solov’eva
    I. L. Gubskii
    T. B. Bukharova
    L. V. Gubskii
    D. V. Goldstein
    K. N. Yarygin
    Bulletin of Experimental Biology and Medicine, 2020, 168 : 566 - 573
  • [49] Neural stem cells - a versatile tool for cell replacement and gene therapy in the central nervous system
    Ourednik, V
    Ourednik, J
    Park, KI
    Snyder, EY
    CLINICAL GENETICS, 1999, 56 (04) : 267 - 278
  • [50] Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease
    Leah R Hanson
    William H Frey
    BMC Neuroscience, 9